ClinicalTrials.gg
Not yet recruitingNCT07938632Updated Nov 16, 2026

TL-925 for the Treatment of Allergic Conjunctivitis

A Phase 2 interventional study of TL-925 and Placebo in Allergic Conjunctivitis of Both Eyes, sponsored by Telios Pharma, Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Telios Pharma, Inc. · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.

Planned enrollment
42nd of 90
100 · median 94
Started
2026
with 3 others
Phase 2
25 of 95
4 open now
Registered
95th of 95
by date
Lead sponsor
5 of 95
Telios Pharma, Inc.

Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 42nd largest by planned enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2026, is one of 25 in phase 2, and was the 95th registered.

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 18 are open to participants now.

Browse Conjunctivitis, Allergic studies →

Open to participants now

6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Conjunctivitis, Allergic with a site in United States, or all of them as a file.
02

Study summary

In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 100 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.

The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.

03

Conditions studied

  • Allergic Conjunctivitis of Both Eyes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged 18 years or older
  • Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test Conducted at Visit 1 or within the past 60 months
  • Positive bilateral CAC reaction
  • Calculated best-corrected visual acuity
  • Female subjects of and their male partners must both use a highly effective method during the study

Exclusion criteria

Exclusion Criteria:

  • Any systemic or ocular disease currently producing ocular redness and/or ocular discomfort, or that may interfere with the conduct of the study
  • Any ocular surgical intervention within three months prior to randomization and/or a history of refractive surgery within six months prior to randomization
  • Any ongoing ocular infection (bacterial, viral, or fungal)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    TL-925 Arm

    Subjects will be dosed in clinic.

    Drug: TL-925

  • Placebo comparator
    Placebo Arm

    Subjects will be dosed in clinic.

    Drug: Placebo

Interventions

  • DrugTL-925

    TL-925 is an eye drop.

  • DrugPlacebo

    The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.

06

What researchers measure

Primary outcomes

  1. Ocular Itching Score

    Ocular itching score will be reported by the subject at 3 timepoints before and after CAC

    Time frame: Day 2, Day 16 and Day 23

  2. Conjunctival Redness Score

    Conjunctival redness score will be evaluated by the investigator at 3 timepoints before and after CAC

    Time frame: Day 2, Day 16 and Day 23

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 16, 2026
StartEst.
Dec 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938632
Lead sponsor
Telios Pharma, Inc.
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

John Mei
Contact
jmei@teliospharma.com
650-209-8127

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TL-925

Start the discussion